Skip to Content
Merck
  • WSB1 overcomes oncogene-induced senescence by targeting ATM for degradation.

WSB1 overcomes oncogene-induced senescence by targeting ATM for degradation.

Cell research (2016-12-14)
Jung Jin Kim, Seung Baek Lee, Sang-Yeop Yi, Sang-Ah Han, Sun-Hyun Kim, Jong-Min Lee, Seo-Yun Tong, Ping Yin, Bowen Gao, Jun Zhang, Zhenkun Lou
ABSTRACT

Oncogene-induced senescence (OIS) or apoptosis through the DNA-damage response is an important barrier of tumorigenesis. Overcoming this barrier leads to abnormal cell proliferation, genomic instability, and cellular transformation, and finally allows cancers to develop. However, it remains unclear how the OIS barrier is overcome. Here, we show that the E3 ubiquitin ligase WD repeat and SOCS box-containing protein 1 (WSB1) plays a role in overcoming OIS. WSB1 expression in primary cells helps the bypass of OIS, leading to abnormal proliferation and cellular transformation. Mechanistically, WSB1 promotes ATM ubiquitination, resulting in ATM degradation and the escape from OIS. Furthermore, we identify CDKs as the upstream kinase of WSB1. CDK-mediated phosphorylation activates WSB1 by promoting its monomerization. In human cancer tissue and in vitro models, WSB1-induced ATM degradation is an early event during tumorigenic progression. We suggest that WSB1 is one of the key players of early oncogenic events through ATM degradation and destruction of the tumorigenesis barrier. Our work establishes an important mechanism of cancer development and progression in premalignant lesions.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-WSB1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Sigma-Aldrich
Z-Leu-Leu-Leu-al, ≥90% (HPLC)
Sigma-Aldrich
MISSION® esiRNA, targeting human WSB1
Sigma-Aldrich
MISSION® esiRNA, targeting human ATM